Moderna's respiratory syncytial virus vaccine shows 83.7% efficacy, shares rise after hours
BeritK/iStock via Getty Images


Moderna (NASDAQ:MRNA) on Tuesday said a late-stage trial of its investigational respiratory syncytial virus (RSV) vaccine candidate met its main efficacy goals.
Shares of the vaccine maker rose 4.4% to $199 in postmarket trade.
The vaccine candidate, mRNA-1345, showed an efficacy of 83.7% against RSV lower respiratory tract disease in older adults, Moderna (MRNA) said in a statement.

The results of the late-stage trial, called ConquerRSV, were reviewed by an independent data and safety monitoring board, MRNA said.
The vaccine candidate was generally well-tolerated, with no safety concerns identified by the board, MRNA added.
The company plans to submit mRNA-1345 for regulatory approval.